A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

It’s the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for?

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.